Evidence map›Paper›PMID 37373787›Full record

ArticleJournal of clinical medicine2023

Uncovering Predictors of Lipid Goal Attainment in Type 2 Diabetes Outpatients Using Logic Learning Machine: Insights from the AMD Annals and AMD Artificial Intelligence Study Group.

Davide Masi, Rita Zilich, Riccardo Candido, Annalisa Giancaterini, Giacomo Guaita, Marco Muselli, Paola Ponzani, Pierluigi Santin, Damiano Verda, Nicoletta Musacchio and 1 more

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Davide MasiDepartment of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0003-0820-633X
Rita ZilichMix-x SRL, 10015 Ivrea, Italy.
Riccardo CandidoAssociazione Medici Diabetologi, Giuliano Isontina University Health Service, 34149 Trieste, Italy.
Annalisa GiancateriniUOSD Diabetology, Department of Exchange and Nutrition Diseases, Brianza Health Service, Pio XI Hospital, 20833 Desio, Italy.
Giacomo GuaitaDiabetes and Endocrinology Unit, ASL SULCIS, 9016 Iglesias, Italy.
Marco MuselliRulex Innovation Labs, Rulex Inc., 16122 Genoa, Italy.ORCID 0000-0002-9999-2331
Paola PonzaniDiabetes and Metabolic Disease Unit, ASL 4 Liguria, 16043 Chiavari, Italy.
Pierluigi SantinDeimos, 33100 Udine, Italy.
Damiano VerdaRulex Innovation Labs, Rulex Inc., 16122 Genoa, Italy.
Nicoletta MusacchioAssociazione Medici Diabetologi, 20156 Milano, Italy.ORCID 0000-0001-9530-2869
Associazione Medici Diabetologi (AMD) Annals Study Group and AMD Artificial Intelligence Study Group

Funding

Daiichi-Sankyo S.P.A. 0
6 · The paper itself

Abstract

Identifying and treating lipid abnormalities is crucial for preventing cardiovascular disease in diabetic patients, yet only two-thirds of patients reach recommended cholesterol levels. Elucidating the factors associated with lipid goal attainment represents an unmet clinical need. To address this knowledge gap, we conducted a real-world analysis of the lipid profiles of 11.252 patients from the Annals of the Italian Association of Medical Diabetologists (AMD) database from 2005 to 2019. We used a Logic Learning Machine (LLM) to extract and classify the most relevant variables predicting the achievement of a low-density lipoprotein cholesterol (LDL-C) value lower than 100 mg/dL (2.60 mmol/L) within two years of the start of lipid-lowering therapy. Our analysis showed that 61.4% of the patients achieved the treatment goal. The LLM model demonstrated good predictive performance, with a precision of 0.78, accuracy of 0.69, recall of 0.70, F1 Score of 0.74, and ROC-AUC of 0.79. The most significant predictors of achieving the treatment goal were LDL-C values at the start of lipid-lowering therapy and their reduction after six months. Other predictors of a greater likelihood of reaching the target included high-density lipoprotein cholesterol, albuminuria, and body mass index at baseline, as well as younger age, male sex, more follow-up visits, no therapy discontinuation, higher Q-score, lower blood glucose and HbA1c levels, and the use of anti-hypertensive medication. At baseline, for each LDL-C range analysed, the LLM model also provided the minimum reduction that needs to be achieved by the next six-month visit to increase the likelihood of reaching the therapeutic goal within two years. These findings could serve as a useful tool to inform therapeutic decisions and to encourage further in-depth analysis and testing.

Indexed as

artificial intelligencedyslipidemialow-density lipoprotein cholesterolmachine learningtype 2 diabetes

Identifiers

PMID37373787
PMCPMC10299248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.